trending Market Intelligence /marketintelligence/en/news-insights/trending/h3eG4wt6D-Ss27ldneX67g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Venture capital firm Capital Point buys stake in Can-Fite BioPharma

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Venture capital firm Capital Point buys stake in Can-Fite BioPharma

Can-Fite BioPharma Ltd. said Capital Point Ltd. acquired more than 5% of the company's outstanding share capital.

The Israel-based venture capital firm has requested Can-Fite to initiate a shareholders meeting to replace the board.

Can-Fite Biopharma noted that it is conducting a review of Capital Point's letter to determine the appropriate actions.

Petah-Tikva, Israel-based Can-Fite Biopharma is developing products to treat autoimmune-inflammatory and cancer diseases.